Loading
Vinblastine is the vinca alkaloid in ABVD, the standard Hodgkin lymphoma regimen, and was formerly in the cisplatin combinations that first cured testicular cancer.
Vinblastine is a vinca alkaloid that binds tubulin and blocks mitotic spindle formation. It is more myelosuppressive and less neurotoxic than vincristine, which is why the two are chosen for different regimens. Approved in the US in 1965, it is the V in ABVD, the standard chemotherapy for Hodgkin lymphoma, and was in PVB, the cisplatin combination that first cured metastatic testicular cancer. It also features in MVAC for bladder cancer, in treatment of Kaposi sarcoma and Langerhans cell histiocytosis, and with carboplatin for low-grade glioma in children. It is a vesicant that causes severe tissue injury if it leaks from the vein, and myelosuppression is the dose-limiting toxicity. Sixty years on, vinblastine is still curing patients within well-tested combinations.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Tubulin-binding antimitotic; more myelosuppressive and less neurotoxic than vincristine.
1.Vinblastine slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: vinblastine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1965 | Hodgkin lymphoma, testicular cancer, Kaposi sarcoma, choriocarcinoma, breast cancer and others |
Read for the class this product belongs to (vinca alkaloids) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Nodular lymphocyte-predominant Hodgkin lymphoma is rarely fatal when treated with standard Hodgkin lymphoma protocols, so the goal for most patients is to give less treatment, not more; the minority with advanced or variant disease still need better options.
Confirmation, by a different route from HD18, that the interim scan can safely direct de-escalation in advanced Hodgkin lymphoma, and that most of the toxicity of escalated BEACOPP can be avoided in the 84 per cent of patients who respond early.
Radiotherapy cannot be omitted in early-stage favourable Hodgkin lymphoma on the basis of a negative interim scan without a clinically relevant loss of tumour control. The scan is better at identifying who needs more than at identifying who needs less.
The interim scan should be used to intensify treatment in early Hodgkin lymphoma, not to withhold radiotherapy. The 99.0 per cent five-year progression-free survival in the scan-negative favourable group with combined-modality treatment is the number any radiotherapy-sparing strategy has to match.
An interim PET scan after two cycles guides treatment of advanced Hodgkin lymphoma: drop bleomycin if negative, intensify if positive.
PET-negative early Hodgkin lymphoma can be treated with chemotherapy alone at a small cost in relapse, an option many younger patients take to avoid radiation to the chest and neck.
Children with multisystem LCH receive a year of vinblastine and prednisone, and those in whom the disease does not respond quickly are switched early to salvage therapy.
Patients with early favourable Hodgkin lymphoma are cured with two cycles of ABVD and 20 Gy of involved-site radiotherapy; later trials tested whether PET can spare radiotherapy altogether.
Query for this drug: (TITLE:"Vinblastine" OR ABSTRACT:"Vinblastine" OR TITLE:"Velban" OR ABSTRACT:"Velban") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vinblastine, not a curated reading list.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, Extragonadal germ cell tumour, GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group and the tags generic, who-essential.
Shares RAPID: PET-directed therapy for early-stage Hodgkin lymphoma, Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials, A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma, GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma and the tag generic.
Shares Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667), Vindesine, Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma, AHL2011 and the tags generic, who-essential.
Shares LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis, LCH-III, Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2), Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma and the tags generic, who-essential.
Shares Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide, Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma, Extragonadal germ cell tumour, AHL2011 and the tags generic, who-essential.
Shares Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667), Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma, AHL2011, PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study and the tags generic, who-essential.
Shares Testicular germ cell tumours, Cytotoxic chemotherapy and the tags generic, who-essential.
Shares Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Eli Lilly (incl. Loxo), Bladder & urothelial cancer and the tags generic, who-essential.